Nayoung Kim1, Danielle E McCarthy2, Wei-Yin Loh3, Jessica W Cook2, Megan E Piper2, Tanya R Schlam2, Timothy B Baker2. 1. Center for Tobacco Research and Intervention, University of Wisconsin School of Medicine and Public Health, Madison, WI 53711, USA. Electronic address: nkim86@ctri.wisc.edu. 2. Center for Tobacco Research and Intervention, University of Wisconsin School of Medicine and Public Health, Madison, WI 53711, USA. 3. Department of Statistics, University of Wisconsin, Madison, WI 53706, USA.
Abstract
BACKGROUND: Nonadherence to smoking cessation medication is a frequent problem. Identifying pre-quit predictors of nonadherence may help explain nonadherence and suggest tailored interventions to address it. AIMS: Identify and characterize subgroups of smokers based on adherence to nicotine replacement therapy (NRT). METHOD: Secondary classification tree analyses of data from a 2-arm randomized controlled trial of Recommended Usual Care (R-UC, n = 315) versus Abstinence-Optimized Treatment (A-OT, n = 308) were conducted. R-UC comprised 8 weeks of nicotine patch plus brief counseling whereas A-OT comprised 3 weeks of pre-quit mini-lozenges, 26 weeks of nicotine patch plus mini-lozenges, 11 counseling contacts, and 7-11 automated reminders to use medication. Analyses identified subgroups of smokers highly adherent to nicotine patch use in both treatment conditions, and identified subgroups of A-OT participants highly adherent to mini-lozenges. RESULTS: Varied facets of nicotine dependence predicted adherence across treatment conditions 4 weeks post-quit and between 4- and 16-weeks post-quit in A-OT, with greater baseline dependence and greater smoking trigger exposure and reactivity predicting greater medication use. Greater quitting motivation and confidence, and believing that stop smoking medication was safe and easy to use were associated with greater adherence. CONCLUSION:Adherence was especially high in those who were more dependent and more exposed to smoking triggers. Quitting motivation and confidence predicted greater adherence, while negative beliefs about medication safety and acceptability predicted worse adherence. Results suggest that adherent use of medication may reflect a rational appraisal of the likelihood that one will need medication and will benefit from it.
RCT Entities:
BACKGROUND: Nonadherence to smoking cessation medication is a frequent problem. Identifying pre-quit predictors of nonadherence may help explain nonadherence and suggest tailored interventions to address it. AIMS: Identify and characterize subgroups of smokers based on adherence to nicotine replacement therapy (NRT). METHOD: Secondary classification tree analyses of data from a 2-arm randomized controlled trial of Recommended Usual Care (R-UC, n = 315) versus Abstinence-Optimized Treatment (A-OT, n = 308) were conducted. R-UC comprised 8 weeks of nicotine patch plus brief counseling whereas A-OT comprised 3 weeks of pre-quit mini-lozenges, 26 weeks of nicotine patch plus mini-lozenges, 11 counseling contacts, and 7-11 automated reminders to use medication. Analyses identified subgroups of smokers highly adherent to nicotine patch use in both treatment conditions, and identified subgroups of A-OT participants highly adherent to mini-lozenges. RESULTS: Varied facets of nicotine dependence predicted adherence across treatment conditions 4 weeks post-quit and between 4- and 16-weeks post-quit in A-OT, with greater baseline dependence and greater smoking trigger exposure and reactivity predicting greater medication use. Greater quitting motivation and confidence, and believing that stop smoking medication was safe and easy to use were associated with greater adherence. CONCLUSION: Adherence was especially high in those who were more dependent and more exposed to smoking triggers. Quitting motivation and confidence predicted greater adherence, while negative beliefs about medication safety and acceptability predicted worse adherence. Results suggest that adherent use of medication may reflect a rational appraisal of the likelihood that one will need medication and will benefit from it.
Authors: Kevin E Thorpe; Merrick Zwarenstein; Andrew D Oxman; Shaun Treweek; Curt D Furberg; Douglas G Altman; Sean Tunis; Eduardo Bergel; Ian Harvey; David J Magid; Kalipso Chalkidou Journal: J Clin Epidemiol Date: 2009-05 Impact factor: 6.437
Authors: Sonia M Grandi; Mark J Eisenberg; Lawrence Joseph; Jennifer O'Loughlin; Gilles Paradis; Kristian B Filion Journal: Am Heart J Date: 2015-12-17 Impact factor: 4.749
Authors: Tanya R Schlam; Jessica W Cook; Timothy B Baker; Todd Hayes-Birchler; Daniel M Bolt; Stevens S Smith; Michael C Fiore; Megan E Piper Journal: Psychopharmacology (Berl) Date: 2018-04-25 Impact factor: 4.530
Authors: Karen L Cropsey; C Brendan Clark; Erin N Stevens; Samantha Schiavon; Adrienne C Lahti; Peter S Hendricks Journal: Addict Behav Date: 2016-10-23 Impact factor: 3.913
Authors: Amanda L Graham; George D Papandonatos; Sarah Cha; Bahar Erar; Michael S Amato; Nathan K Cobb; Raymond S Niaura; David B Abrams Journal: Nicotine Tob Res Date: 2017-03-01 Impact factor: 4.244
Authors: Zhe He; Shubo Tian; Ankita Singh; Shayok Chakraborty; Shenghao Zhang; Mia Liza A Lustria; Neil Charness; Nelson A Roque; Erin R Harrell; Walter R Boot Journal: Inf Process Manag Date: 2022-07-21 Impact factor: 7.466
Authors: Amanual Getnet Mersha; Gillian Sandra Gould; Michelle Bovill; Parivash Eftekhari Journal: Int J Environ Res Public Health Date: 2020-11-30 Impact factor: 3.390
Authors: Amanual Getnet Mersha; Michelle Kennedy; Parivash Eftekhari; Gillian Sandra Gould Journal: Int J Environ Res Public Health Date: 2021-11-21 Impact factor: 3.390